BACTERIOLOGICAL AND CLINICAL STUDIES ON T-3262 WITH SPECIAL REFERENCE TO RESPIRATORY TRACT INFECTIONS

概要

論文の詳細を見る
We carried out bacteriological and clinical studies on T-3262, a new oral pyridone-carboxylic acid derivative and obtained the following results. 1) The peak MIC of T-3262 against S. aureus was 0.05μg/ml, which was superior to those of OFLX and CPFX. The antibacterial activity against E. coli was almost equal to those of OFLX and CPFX. Except P. mirabilis, MICs of T-3262 against Ggram-negative bacteria, such as Klebsiella, S. marcescens or P. aeruginosa, were almost equal to those of CPFX and superior to those of OFLX. 2) The MIC of T-3262 against some strains of C. psittaci was O.025μg/ml, which was almost equal to that of MINO, and superior to those of EM, OFLX and CPFX. MICs against C. trachomatis were also as low as 0.05-0.1μg/ml. 3) T-3262 was administered to 27 patients with respiratory tract infection at a daily dose of 225-600 mg, b. i. d. or t. i. d., for 3-14 days, and clinical efficacy was evaluated in 25 cases. The efficacy rate was 76.0%(Excellent 2, Good 17, Fair 4 and Poor 2). 4) As side effects, anorexia and insomnia, itching of the anterior chest wall, abdominal fullness and cough were noted in one case each; and, as abnormal laboratory findings, slight elevation of liver enzymes (GOT, GPT, LDH) in 3 cases.
公益社団法人日本化学療法学会の論文